title: Impact of treatment satisfaction on quality of life of patients with acromegaly.
abstract: OBJECTIVE
  To evaluate satisfaction of acromegalic subjects with their medical treatment and its contribution to their quality of life.
  
  
  METHODS
  This cross-sectional study included a total of 159 medications used in 133 subjects with acromegaly (controlled n = 84 and uncontrolled n = 49, female/male: 81/52). Subjects were asked to complete questionnaires on symptoms of depression (BDI) and satisfaction with the medical therapy they received for acromegaly (TSQM). Acromegaly cases also completed Acromegaly Quality of Life Questionnaire (AcroQoL).
  
  
  RESULTS
  Subjects on pegvisomant therapy scored lower on convenience (p = 0.007). Cases on combination therapy had lower domain scores for effectiveness, convenience and global satisfaction in comparison to the cases on monotherapy (p = 0.01, p = 0.01 and p = 0.01, respectively). The time elapsed since diagnosis and the duration of medical therapy were positively correlated with effectiveness score (r = 0.2, p = 0.007 and r = 0.2, p = 0.04, respectively). The AcroQoL score was positively correlated with all domains of TSQM (for effectiveness r = 0.2, p = 0.01; for side effects r = 0.3, p = 0.001; for convenience r = 0.3, p = 0.004 and for global satisfaction r = 0.2, p = 0.01). In contrast, the BDI score was inversely correlated with all domains of TSQM (for effectiveness r = -0.3, p = 0.001; for side effects r = -0.2, p = 0.006; for convenience r = -0.3, p < 0.001 and for global satisfaction r = -0.3, p = 0.001).
  
  
  CONCLUSIONS
  In acromegaly, quality of life, status of depression and satisfaction of the subjects with their treatment are intercorrelated.
authors: Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.
authors: Hasan
authors: H
authors: Kepicoglu
authors: Esra
authors: E
authors: Hatipoglu
authors: Irem
authors: I
authors: Bulut
authors: Ezgi
authors: E
authors: Darici
authors: Naz
authors: N
authors: Hizli
authors: Pinar
authors: P
authors: Kadioglu
mesh_terms: D000172:Acromegaly / Q000188:drug therapy / Q000523:psychology* / Q000628:therapy*; D000328:Adult; D003430:Cross-Sectional Studies; D003863:Depression / Q000523:psychology; D005260:Female; D006727:Hormone Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007018:Hypopituitarism / Q000150:complications / Q000523:psychology; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010549:Personal Satisfaction; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors; D012959:Socioeconomic Factors; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D006727:Hormone Antagonists; D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; C406545:pegvisomant